Dislocation of the HIP JOINT from an abnormal FEMORAL HEAD to the ACETABULUM relationship. It is most often due to ligamentous laxity, abnormal positioning of the joint and various other developmental, congenital factors, and method of delivery (e.g., OLIGOHYDRAMNIOS). When dislocation is diagnosed in neonates it is referred to as CONGENITAL HIP DYSPLASIA.
| Synonym |
|---|
| Developmental Dysplasia of the Hip |
| Developmental Hip Dislocation |
| Developmental Hip Dysplasia |
| Hip Dislocation, Developmental |
| Excerpt | Reference |
|---|---|
| "It is challenging to treat developmental dysplasia of the hip (DDH) classified Crowe III-IV using direct anterior approach (DAA) total hip arthroplasty (THA), and very little is known on its outcome." | ( Bell, CD; Li, J; Liu, Z; Ong, AC; Zhang, J; Zhang, Y, 2021) |
| Timeframe | Studies, This Condition (%) | All Conditions % |
|---|---|---|
| pre-1990 | 0 (0.00) | 23.3326 |
| 1990's | 0 (0.00) | 12.5806 |
| 2000's | 0 (0.00) | 18.1394 |
| 2010's | 0 (0.00) | 28.8240 |
| 2020's | 9 (100.00) | 9.53 |
| Drug | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| benzene | 0 | low | 1 | 0 |
| gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate | 0 | low | 1 | 0 |
| gadolinium dtpa | 0 | low | 1 | 0 |
| Protein | Potency Measurements | Inhibition Measurements | Activation Measurements | Drugs |
|---|---|---|---|---|
| Chain A, Integrase | 0 | 1 | 0 | 1 |
| Chain A, Integrase | 0 | 1 | 0 | 1 |
| Chain A, T4 LYSOZYME | 0 | 0 | 1 | 1 |
| Chain A, GCN4P1 | 0 | 0 | 1 | 1 |
| Chain B, GCN4P1 | 0 | 0 | 1 | 1 |
| Chain C, GCN4P1 | 0 | 0 | 1 | 1 |
| Chain A, T4 LYSOZYME | 0 | 0 | 1 | 1 |
| Chain A, T4 LYSOZYME | 0 | 0 | 1 | 1 |
| Chain A, Replicase polyprotein 1ab | 0 | 1 | 0 | 1 |
| Chain A, 3C-like proteinase | 0 | 1 | 0 | 1 |
| pregnane X receptor | 1 | 0 | 0 | 1 |
| thyroid stimulating hormone receptor | 1 | 0 | 0 | 1 |
| progesterone receptor | 1 | 0 | 0 | 1 |
| retinoid X nuclear receptor alpha | 1 | 0 | 0 | 1 |
| peroxisome proliferator-activated receptor delta | 1 | 0 | 0 | 1 |
| cellular tumor antigen p53 isoform a | 1 | 0 | 0 | 1 |
| Endolysin | 0 | 0 | 1 | 1 |
| Cellular tumor antigen p53 | 1 | 0 | 0 | 1 |
| Integrin beta-3 | 1 | 0 | 0 | 1 |
| Integrin alpha-IIb | 1 | 0 | 0 | 1 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | ||||